Syntopix Directors Dealings

12 May 2011
Syntopix Directors Dealings

Syntopix Group plc Directors Dealings announcement

Syntopix Group plc (AIM:SYN), the speciality pharmaceutical research and development company focused on topical antimicrobial innovations for products in the medicine and consumer healthcare markets, has today been notified that, on 10 May 2011, Tom Bannatyne, Chairman of the Company, acquired 140,000 ordinary shares of 10p each in the Company, at a price of 48p per share. Following this purchase Mr Bannatyne has a beneficial interest in 646,467 ordinary shares representing approximately 6.03 per cent. of the Company's issued share capital.